TheStreet Lowers Boston Scientific Co. (BSX) to C+
- Author: Zachary Reyes Apr 12, 2017,
Apr 12, 2017, 20:06
The fund owned 1,866,739 shares of the company's stock after buying an additional 13,459 shares during the period. Thrivent Financial for Lutherans' holdings in Boston Scientific were worth $1,026,000 at the end of the most recent quarter. Victory Inc holds 0.1% of its portfolio in First Financial Bancorp (NASDAQ:FFBC) for 1.37 million shares. Prudential Financial Inc. now owns 4,380,019 shares of the company's stock worth $104,245,000 after buying an additional 2,417,148 shares in the last quarter. Janus Capital Management LLC raised its stake in shares of Boston Scientific by 17.8% in the fourth quarter. Bank of Montreal Can now owns 591,208 shares of the company's stock valued at $14,073,000 after buying an additional 21,680 shares in the last quarter. Boston Private Wealth LLC now owns 22,890 shares of the company's stock valued at $545,000 after buying an additional 85 shares during the last quarter. The one year target is $24.46 with zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the company a sell. Wade G W & Inc. increased its position in Boston Scientific by 0.9% in the third quarter. The number of shares now owned by investors are 1.37 bln. The stock is above its 52-week low with 28.31% and is in the wake of its 52-week high with -4.41%.
Today there are 1,363,488,000 shares in issue of Boston Scientific BSX which are now trading at 24.51 which brings the business's market capitalisation to 33.42B Dollars. Its shares have trimmed -18.75% since hitting a peak level of $1.92 on February 15, 2017. The price to earnings growth is 7.83 and the price to sales ratio is 17.
The volume of the particular stock is the shares bought and sold in a single trading day.
Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 2nd. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.29 by $0.01. Net profit margin of the company was recorded at 4.1 percent, operating profit margin was 5.3 percent, whereas gross profit margin stands at 71.5 percent. The firm earned $2.19 billion during the quarter, compared to analyst estimates of $2.16 billion. During the same quarter in the previous year, the company earned $0.26 EPS. Year to Date (YTD) performance of Boston Scientific Corporation (BSX) is 13.36 percent while its Performance (Week) is -1.61 percent and Performance (month) is at -0.49 percent. They expect $0.69 EPS, down 10.39% or $0.08 from last year's $0.77 per share.
ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of global trademark and copyright legislation. Finally, Northland Securities reissued a "positive" rating on shares of Boston Scientific in a report on Thursday, February 23rd. TheStreet raised Boston Scientific from a "c+" rating to a "b" rating in a research report on Tuesday, January 17th.
Synergy Pharmaceuticals Inc's consensus price target is around $11.03 a share.
Several investment firms issued their expert ratings on Boston Scientific Corporation (BSX) in which Argus Research Upgrades Boston Scientific Corporation (BSX) to Buy by settling a price target of $33 on 9/01/16. It has ranged in price between $24.45-$24.79 after having started the session at $24.66 as compared to the previous trading day's close of $24.65. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Price targets frequently change, depending on the outlook for a company's earnings. Finally, BTIG Research reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Sunday, February 5th. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. Following the sale, the senior vice president now owns 34,267 shares in the company, valued at $851,192.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
In other Boston Scientific news, EVP Michael P. Phalen sold 79,045 shares of Boston Scientific stock in a transaction dated Wednesday, March 29th. They now have a Dollars 25 price target on the stock. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 1.63, indicating analysts in general look favorably on the company's future prospects. The disclosure for this sale can be found here. The Moving Average SMA50 is -0.21% while SMA200 is 5.65%.